TORONTO--(BUSINESS WIRE)--According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, thoracic aortic stent grafts, recently approved and reimbursed in Japan, will show strong growth in procedure volumes since they can treat aneurysms previously requiring invasive and dangerous surgery.
Thoracic endovascular aortic repair (TEVAR), a minimally invasive approach to repairing thoracic aortic aneurysms (TAAs), was introduced to Japan relatively recently and has led to rapid growth in these interventions. Before the introduction of thoracic aortic stent grafts, many Japanese physicians used self-made stent grafts for TAAs. As a result, these physicians were already familiar with TEVAR and quickly switched to the newly approved devices. Resulting growth in TEVAR volumes has been high.
The first stent graft approved in Japan was W. L. Gore’s TAG Thoracic Endoprosthesis in 2008. Since then, Medtronic received approval for its Talent Thoracic Stent Graft in 2009. Cook Medical recently joined W. L. Gore and Medtronic receiving approval for its Zenith TX2 in March 2011.
“Traditional surgical repair of the thoracic aorta is both invasive and severe, with many potential negative side effects,” said MRG Analyst Fareed Hameed. “Many patients with thoracic artery disease have been treated nonsurgically because the risks of surgery were considered unacceptable. Some of these patients were diagnosed as long as ten years ago. The result is a large pool of patients who can benefit from a TEVAR procedure, creating a significant demand for thoracic aortic stent grafts.”
In 2010 there were over 1,900 thoracic aortic repairs using stent grafts. This number will reach over 2,900 annually by 2015. The market itself will grow from nearly $48 million in 2010 to nearly $60 million in 2015, an average growth rate of 4.5 percent annually. While the number of procedures will increase, average selling prices will decline due to reimbursement cuts.
Millennium Research Group’s Japanese Markets for Peripheral Vascular Devices 2011 report includes procedure, unit, average selling price and revenue information, along with market drivers and limiters, as well as competitive landscape for PV stents, percutaneous transluminal angioplasty (PTA) balloon catheters, embolic protection devices (EPDs), inferior vena cava filters (IVCFs), aortic stent grafts, synthetic surgical grafts and various PV accessory devices in Japan.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.